{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T21:40:21Z","timestamp":1774474821120,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ijrobp.2015.09.020","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T18:12:07Z","timestamp":1443204727000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial"],"prefix":"10.1016","volume":"94","clinical-trial-number":[{"clinical-trial-number":"nct01368588","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01952223","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-3409","authenticated-orcid":false,"given":"Pierre","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Lesaunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Mesgouez-Nebout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Deniau-Alexandre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Th\u00e9odore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Krakowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Berdah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Baciuchka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Davin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Habibian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Laplanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.09.020_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0022-5347(05)67035-8","article-title":"Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer","volume":"164","author":"Blute","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.1997.03540420041027","article-title":"Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update","volume":"277","author":"Partin","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: The essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2013.05.029","article-title":"Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection","volume":"109","author":"Abdollah","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2013.06.046","article-title":"The role of elective pelvic radiotherapy in clinically node-negative prostate cancer: A systematic review","volume":"110","author":"Dirix","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/0360-3016(88)90225-8","article-title":"Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06","volume":"15","author":"Asbell","year":"1988","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib8","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib9","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0360-3016(94)90006-X","article-title":"PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation","volume":"30","author":"Hanks","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejca.2011.10.015","article-title":"A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: A planned analysis of response, toxicity and quality of life in the GETUG 12 trial","volume":"48","author":"Fizazi","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib14","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2004.05.033","article-title":"The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: Feasibility and acute toxicity","volume":"60","author":"Beckendorf","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M D Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib16","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(95)00063-5","article-title":"Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone","volume":"32","author":"Shipley","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0021-9681(78)90043-7","article-title":"Estimation of confidence limits for the cumulative probability of survival in life table analysis","volume":"31","author":"Rothman","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2011.02.024","article-title":"Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: Results of a matched analysis","volume":"59","author":"Briganti","year":"2011","journal-title":"Eur Urol"},{"issue":"suppl","key":"10.1016\/j.ijrobp.2015.09.020_bib22","article-title":"A phase III protocol of androgen suppression (AS) and 3DCRT\/IMRT versus AS and 3DCRT\/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)","volume":"33","author":"Sandler","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","article-title":"Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer","volume":"50","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijrobp.2009.05.006","article-title":"Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer","volume":"77","author":"Bayley","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.09.020_bib25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.eururo.2014.08.076","article-title":"Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: Introducing the Prostate Cancer Consortium in Europe","volume":"67","author":"Fizazi","year":"2015","journal-title":"Eur Urol"}],"updated-by":[{"DOI":"10.1016\/j.ijrobp.2016.01.026","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000}}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615264760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615264760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T19:01:17Z","timestamp":1529521277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615264760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0360301615264760"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.09.020","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ijrobp.2016.01.026","asserted-by":"object"}]},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}